Publication date: Jun 18, 2025
While COVID-19 has transitioned from a pandemic to an endemic state, the management of its persistent complications continues to present substantial clinical challenges. Tocilizumab, an interleukin-6 receptor antagonist endorsed by the World Health Organization (WHO) for severe COVID-19 management, remains a critical therapeutic intervention. This systematic evaluation provides a comprehensive assessment of tocilizumab’s safety and efficacy profile to inform clinical decision-making. The study involved exhaustive search across multiple databases (PubMed, SCOPUS, WoS, BIOSIS) utilizing MeSH terms and Boolean operators to identify relevant studies. Methodological worthiness was rigorously evaluated utilizing the Risk of Bias 2 (RoB 2) tool. The statistical analysis of the findings incorporated one-way ANOVA, Mann-Whitney U tests, and Pearson’s correlation coefficient (r) with 95 % confidence intervals to quantify adverse effects and therapeutic outcomes. The analysis of nine studies encompassing diverse demographic populations (ages ≥2 years, both sexes) established a clear safety profile for tocilizumab. The treatment demonstrated a statistically important association (P
| Concepts | Keywords |
|---|---|
| Covid | COVID-19 |
| Databases | Efficacy |
| Pandemic | Monoclonal antibody |
| Rob | Safety |
| Worthiness | Tocilizumab |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tocilizumab |
| disease | MESH | COVID-19 |
| disease | MESH | complications |
| disease | IDO | intervention |